Black, James R. M. http://orcid.org/0000-0001-5598-7752
McGranahan, Nicholas http://orcid.org/0000-0001-9537-4045
Article History
Accepted: 28 January 2021
First Online: 16 March 2021
Competing interests
: The authors declare no competing interests. N.M. has received consultancy fees and has stock options in Achilles Therapeutics. N.M. holds European patents relating to targeting neoantigens (PCT/EP2016/ 059401), identifying patient response to immune checkpoint blockade (PCT/ EP2016/071471), determining HLA LOH (PCT/GB2018/052004), predicting survival rates of patients with cancer (PCT/GB2020/050221). J.R.M.B. declares no competing interests.